MG4101

BIOLOGICAL3 trials

Sponsors

Samsung Medical Center, GC Cell Corporation, Seoul National University Hospital

Conditions

Acute Myeloid LeukemiaHepatocellular Carcinoma

Phase 2

to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)

CompletedNCT02008929

Samsung Medical CenterHepatocellular Carcinoma

Start: 2014-08-31End: 2015-10-31Updated: 2015-12-03

A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma

CompletedNCT02854839

GC Cell CorporationHepatocellular Carcinoma

Start: 2016-11-28End: 2019-09-17Updated: 2019-09-26

MG4101 for Refractory or Relapsed AML

CompletedNCT03349502

Seoul National University HospitalAcute Myeloid Leukemia

Start: 2017-11-01End: 2020-04-30Updated: 2023-04-18

Related Papers

Adjuvant therapy using <i>ex vivo</i>-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study.

2021-05-0110 citations